Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?
Cue Biopharma, Inc. (NASDAQ:CUE) reported positive Phase 2 results for CUE-221 on September 20.
Cue Biopharma Inc. (CUE)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Driehaus Capital Richard Driehaus | 292,144 | $9,220,065 | 0.05% | |
| 2. | Ikarian Capital Neil Shahrestani | 104,364 | $3,293,728 | 0.35% | |
| 3. | StemPoint Capital Michelle Ross | 66,995 | $2,114,362 | 0.36% | |
| 4. | ADAR1 Capital Management Daniel Schneeberger | 55,193 | $1,741,891 | 0.08% | |
| 5. | Lion Point Didric Cederholm | 52,928 | $1,670,408 | 7.99% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.30 | 77,417 | $23,348.97 | 323,857 | 2025-12-30 | Filing | |
| $0.31 | 78,116 | $24,325.32 | 246,440 | 2025-12-30 | Filing | |
| $0.32 | 86,947 | $27,596.98 | 168,324 | 2025-12-30 | Filing | |
| $0.30 | 77,148 | $23,167.54 | 81,377 | 2025-12-30 | Filing | |
| $0.31 | 4,229 | $1,308.45 | 4,229 | 2025-12-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $28.05 | 1,844 | $51,724.20 | 116,701 | 2026-10-12 | Filing | |
| $28.05 | 1,144 | $32,089.20 | 47,817 | 2026-10-12 | Filing | |
| $28.05 | 1,087 | $30,490.35 | 694,908 | 2026-10-12 | Filing | |
| $27.50 | 10,000 | $275,000.00 | 695,995 | 2026-10-12 | Filing | |
| $31.13 | 4 | $124.52 | 118,545 | 2026-08-13 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,133 | $288,011 | 0.01% | |
| 2. | 300 | $7,761 | 0% | |
| 3. | 200 | $5,174 | 0% | |
| 4. | 99 | $2,561 | 0% | |
| 5. | 66 | $1,707 | 0% |
News See All
10 Unstoppable Stocks That Could Double Your Money
In this article, we will discuss the 10 Unstoppable Stocks That Could Double Your Money.
Cue Biopharma, Inc. (NASDAQ:CUE) Q2 2024 Earnings Call Transcript
Cue Biopharma, Inc. (NASDAQ:CUE) Q2 2024 Earnings Call Transcript August 19, 2024 Operator: Good day, and welcome to the Cue Biopharma Second Quarter 2024 Earnings Call.
Cue Biopharma, Inc. (NASDAQ:CUE) Q3 2023 Earnings Call Transcript
Cue Biopharma, Inc. (NASDAQ:CUE) Q3 2023 Earnings Call Transcript November 11, 2023 Operator: Good afternoon, ladies and gentlemen, and welcome to the Cue Biopharma Third Quarter 2023 Earnings Call.
Cue Biopharma, Inc. (NASDAQ:CUE) Q2 2023 Earnings Call Transcript
Cue Biopharma, Inc. (NASDAQ:CUE) Q2 2023 Earnings Call Transcript August 9, 2023 Operator: Greetings, and welcome to the Cue Biopharma Investor Update Call.
Cue Biopharma, Inc. (NASDAQ:CUE) Q4 2022 Earnings Call Transcript
Cue Biopharma, Inc. (NASDAQ:CUE) Q4 2022 Earnings Call Transcript March 21, 2023 Operator: Greetings, and welcome to the Cue Biopharma Fourth Quarter and Full Year 2022 Earnings Call.
Hedge Funds Have Never Been This Bullish On Cue Biopharma, Inc. (CUE)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Hedge Fund Resource Center